

Supplemental Material

The CARDiogram consortium: Sources of Funding

The **ADVANCE** study was supported by a grant from the Reynold's Foundation and NHLBI grant HL087647.

Genetic analyses of **CADomics** were supported by a research grant from Boehringer Ingelheim. Recruitment and analysis of the CADomics cohort was supported by grants from Boehringer Ingelheim and PHILIPS medical Systems, by the Government of Rheinland-Pfalz in the context of the “Stiftung Rheinland-Pfalz für Innovation”, the research program “Wissen schafft Zukunft” and by the Johannes-Gutenberg University of Mainz in the context of the “Schwerpunkt Vaskuläre Prävention” and the “MAIFOR grant 2001”, by grants from the Fondation de France, the French Ministry of Research, and the Institut National de la Santé et de la Recherche Médicale.

The **deCODE** CAD/MI Study was sponsored by NIH grant, National Heart, Lung and Blood Institute R01HL089650-02.

The German MI Family Studies (**GerMIFS I-III (KORA)**) were supported by the Deutsche Forschungsgemeinschaft and the German Federal Ministry of Education and Research (BMBF) in the context of the German National Genome Research Network (NGFN-2 and NGFN-plus), the EU funded integrated projects Cardiogenics (LSHM-CT-2006-037593) and ENGAGE, and the bi-national BMBF/ANR funded project CARDomics (01KU0908A).

LURIC has received funding from the EU framework 6 funded Integrated Project “Bloodomics” (LSHM-CT-2004-503485), the EU framework 7 funded Integrated Project AtheroRemo (HEALTH-F2-2008-201668) and from Sanofi/Aventis, Roche, Dade Behring/Siemens, and AstraZeneca.

The **MIGen** study was funded by the US National Institutes of Health (NIH) and National Heart, Lung, and Blood Institute’s STAMPEED genomics research program through R01 HL087676. Ron Do from the MIGen study is supported by a Canada Graduate Doctoral Scholarship from the Canadian Institutes of Health Research.

Recruitment of **PennCATH** was supported by the Cardiovascular Institute of the University of Pennsylvania. Recruitment of the **MedStar** sample was supported in part by the MedStar Research Institute and the Washington Hospital Center and a research grant from GlaxoSmithKline. Genotyping of PennCATH and Medstar was performed at the Center for Applied Genomics at the Children’s Hospital of Philadelphia and supported by GlaxoSmithKline through an Alternate Drug Discovery Initiative research alliance award (M. P. R. and D. J. R.) with the University of Pennsylvania School of Medicine.

The **Ottawa Heart Genomic Study** was supported by CIHR #MOP--82810 (R. R.), CFI #11966 (R. R.), HSFO #NA6001 (R. McP.), CIHR #MOP172605 (R. McP.), CIHR #MOP77682 (A. F. R. S.).

The **WTCCC** Study was funded by the Wellcome Trust. Recruitment of cases for the WTCCC Study was carried out by the British Heart Foundation (BHF) Family Heart Study Research Group and supported by the BHF and the UK Medical Research Council. N. J. S. and S. G. B. hold chairs funded

by the British Heart Foundation. N. J. S. and A.H.G are also supported by the Leicester NIHR Biomedical Research Unit in Cardiovascular Disease and the work described in this paper is part of the research portfolio of the Leicester NIHR Biomedical Research Unit.

The **Age, Gene/Environment Susceptibility Reykjavik Study** has been funded by NIH contract N01-AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament).

The **Cleveland Clinic GeneBank** study was supported by NIH grants P01 HL098055, P01HL076491-06, R01DK080732, P01HL087018, and 1R01HL103931-01.

The collection of clinical and sociodemographic data in the **Dortmund Health Study** was supported by the German Migraine- & Headache Society (DMKG) and by unrestricted grants of equal share from Astra Zeneca, Berlin Chemie, Boots Healthcare, Glaxo-Smith-Kline, McNeil Pharma (former Woelm Pharma), MSD Sharp & Dohme and Pfizer to the University of Muenster. Blood collection was done through funds from the Institute of Epidemiology and Social Medicine, University of Muenster.

The **EPIC-Norfolk study** is supported by the Medical Research Council UK and Cancer Research UK.

The **EpiDREAM study** is supported by the Canadian Institutes fo Health Research, Heart and Stroke Foundation of Ontario, Sanofi-Aventis, GlaxoSmithKline and King Pharmaceuticals.

Funding for Andrew Lotery from the **LEEDS** study was provided by tha T.F.C. Frost charity and the Macular Disease Society.

The **Rotterdam Study** is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly; The Netherlands Heart Foundation; the Ministry of Education, Culture and Science; the Ministry of Health Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. Support for genotyping was provided by the Netherlands Organization for Scientific Research (NWO) (175.010.2005.011, 911.03.012), the Netherlands Genomics Initiative (NGI)/ NWO project nr. 050-060-810 and Research Institute for Diseases in the Elderly (RIDE). Abbas Dehghan is supported by a grant from NWO (Vici, 918-76-619).

The **SAS** study was funded by the British Heart Foundation.

The Swedish Research Council, the Swedish Heart & Lung Foundation and the Stockholm County Council (ALF) supported the **SHEEP** study.

SMILE was funded by the Netherlands Heart foundation (NHS 92345). Dr Rosendaal is a recipient of the Spinoza Award of the Netherlands Organisation for Scientific Research (NWO) which was used for part of this work.

The **Verona Heart Study** was funded by grants from the Italian Ministry of University and Research, the Veneto Region, and the Cariverona Foundation, Verona.

The **Atherosclerosis Risk in Communities Study** is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. The authors thank the staff and participants of the ARIC study for their important contributions.

The **KORA** (Kooperative Gesundheitsforschung in der Region Augsburg) research platform was initiated and financed by the Helmholtz Zentrum München - National Research Center for Environmental Health, which is funded by the German Federal Ministry of Education, Science, Research and Technology and by the State of Bavaria. Part of this work was financed by the German National Genome Research Network (NGFN-2 and NGFNPlus) and within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ.

Work described in this paper is part of the research portfolio supported by the Leicester NIHR Biomedical Research Unit in Cardiovascular Disease.

This work forms part of the research themes contributing to the translational research portfolio of Barts and the London Cardiovascular Biomedical Research Unit which is supported and funded by the National Institute of Health Research. The work was also funded by the EU funded project ENGAGE.

Members of the CARDIoGRAM Consortium

Executive Committee: Sekar Kathiresan^{1,2,3}, Muredach P. Reilly⁴, Nilesh J. Samani^{5,6}, Heribert Schunkert^{7,79}

Executive Secretary: Jeanette Erdmann^{7,79}

Steering Committee: Themistocles L. Assimes⁸, Eric Boerwinkle⁹, Jeanette Erdmann^{7,79}, Alistair Hall¹⁰, Christian Hengstenberg¹¹, Sekar Kathiresan^{1,2,3}, Inke R. König¹², Reijo Laaksonen¹³, Ruth McPherson¹⁴, Muredach P. Reilly⁴, Nilesh J. Samani^{5,6}, Heribert Schunkert^{7,79}, John R. Thompson¹⁵, Unnur Thorsteinsdottir^{16,17}, Andreas Ziegler¹²

Statisticians: Inke R. König¹² (chair), John R. Thompson¹⁵ (chair), Devin Absher¹⁸, Li Chen¹⁹, L. Adrienne Cupples^{20,21}, Eran Halperin²², Mingyao Li²³, Kiran Musunuru^{1,2,3}, Michael Preuss^{12,7}, Arne Schillert¹², Gudmar Thorleifsson¹⁶, Benjamin F. Voight^{2,3,24}, George A. Wells²⁵

Writing group: Themistocles L. Assimes⁸, Panos Deloukas²⁶, Jeanette Erdmann^{7,79}, Hilma Holm¹⁶, Sekar Kathiresan^{1,2,3}, Inke R. König¹², Ruth McPherson¹⁴, Muredach P. Reilly⁴, Robert Roberts¹⁴, Nilesh J. Samani^{5,6}, Heribert Schunkert^{7,79}, Alexandre F. R. Stewart¹⁴

ADVANCE: Devin Absher¹⁸, Themistocles L. Assimes⁸, Stephen Fortmann⁸, Alan Go²⁷, Mark Hlatky⁸, Carlos Iribarren²⁷, Joshua Knowles⁸, Richard Myers¹⁸, Thomas Quertermous⁸, Steven Sidney²⁷, Neil Risch²⁸, Hua Tang²⁹

CADomics: Stefan Blankenberg³⁰, Tanja Zeller³⁰, Arne Schillert¹², Philipp Wild³⁰, Andreas Ziegler¹², Renate Schnabel³⁰, Christoph Sinning³⁰, Karl Lackner³¹, Laurence Tiret³², Viviane Nicaud³², Francois Cambien³², Christoph Bickel³⁰, Hans J. Rupprecht³⁰, Claire Perret³², Carole Proust³², Thomas Münzel³⁰

CHARGE: Maja Barbalic³³, Joshua Bis³⁴, Eric Boerwinkle⁹, Ida Yii-Der Chen³⁵, L. Adrienne Cupples^{20,21}, Abbas Dehghan³⁶, Serkalem Demissie-Banjaw^{37,21}, Aaron Folsom³⁸, Nicole Glazer³⁹, Vilmundur Gudnason^{40,41}, Tamara Harris⁴², Susan Heckbert⁴³, Daniel Levy²¹, Thomas Lumley⁴⁴, Kristin Marcianti⁴⁵, Alanna Morrison⁴⁶, Christopher J. O'Donnell⁴⁷, Bruce M. Psaty⁴⁸, Kenneth Rice⁴⁹, Jerome I. Rotter³⁵, David S. Siscovick⁵⁰, Nicholas Smith⁴³, Albert Smith^{40,41}, Kent D. Taylor³⁵, Cornelia van Duijn³⁶, Kelly Volcik⁴⁶, Jaqueline Whitteman³⁶, Vasam Ramachandran⁵¹, Albert Hofman³⁶, Andre Uitterlinden^{52,36}

deCODE: Solveig Gretarsdottir¹⁶, Jeffrey R. Gulcher¹⁶, Hilma Holm¹⁶, Augustine Kong¹⁶, Kari Stefansson^{16,17}, Gudmundur Thorgeirsson^{53,17}, Karl Andersen^{53,17}, Gudmar Thorleifsson¹⁶, Unnur Thorsteinsdottir^{16,17}

GERMIFS I and II: Jeanette Erdmann^{7,79}, Marcus Fischer¹¹, Anika Grosshennig^{12,7}, Christian Hengstenberg¹¹, Inke R. König¹², Wolfgang Lieb⁵⁴, Patrick Linsel-Nitschke⁷, Michael Preuss^{12,7}, Klaus Stark¹¹, Stefan Schreiber⁵⁵, H.-Erich Wichmann^{56,58,59}, Andreas Ziegler¹², Heribert Schunkert⁸⁰

GERMIFS III (KORA): Zouhair Aherrahrou^{7,79}, Petra Bruse^{7,79}, Angela Doering⁵⁶, Jeanette Erdmann^{7,79}, Christian Hengstenberg¹¹, Thomas Illig⁵⁶, Norman Klopp⁵⁶, Inke R. König¹², Patrick Diemert⁷, Christina Loley^{12,7}, Anja Medack^{7,79}, Christina Meisinger⁵⁶, Thomas Meitinger^{57,60}, Janja Nahrstedt^{12,7}, Annette Peters⁵⁶, Michael Preuss^{12,7}, Klaus Stark¹¹, Arnika K. Wagner⁷, H.-Erich Wichmann^{56,58,59}, Christina Willenborg^{7,79}, Andreas Ziegler¹², Heribert Schunkert^{7,79}

LURIC/AtheroRemo: Bernhard O. Böhm⁶¹, Harald Dobnig⁶², Tanja B. Grammer⁶³, Eran Halperin²², Michael M. Hoffmann⁶⁴, Marcus Kleber⁶⁵, Reijo Laaksonen¹³, Winfried März^{63,66,67}, Andreas Meinitzer⁶⁶, Bernhard R. Winkelmann⁶⁸, Stefan Pilz⁶², Wilfried Renner⁶⁶, Hubert Scharnagl⁶⁶, Tatjana Stojakovic⁶⁶, Andreas Tomaschitz⁶², Karl Winkler⁶⁴

MIGen: Benjamin F. Voight^{2,3,24}, Kiran Musunuru^{1,2,3}, Candace Guiducci³, Noel Burt³, Stacey B. Gabriel³, David S. Siscovick⁵⁰, Christopher J. O'Donnell⁴⁷, Roberto Elosua⁶⁹, Leena Peltonen⁴⁹, Veikko Salomaa⁷⁰, Stephen M. Schwartz⁵⁰, Olle Melander²⁶, David Altshuler^{71,3}, Sekar Kathiresan^{1,2,3}

OHGS: Alexandre F. R. Stewart¹⁴, Li Chen¹⁹, Sonny Dandona¹⁴, George A. Wells²⁵, Olga Jarinova¹⁴, Ruth McPherson¹⁴, Robert Roberts¹⁴

PennCATH/MedStar: Muredach P. Reilly⁴, Mingyao Li²³, Liming Qu²³, Robert Wilensky⁴, William Matthai⁴, Hakon H. Hakonarson⁷², Joe Devaney⁷³, Mary Susan Burnett⁷³, Augusto D. Pichard⁷³, Kenneth M. Kent⁷³, Lowell Satler⁷³, Joseph M. Lindsay⁷³, Ron Waksman⁷³, Christopher W. Knouff⁷⁴, Dawn M. Waterworth⁷⁴, Max C. Walker⁷⁴, Vincent Mooser⁷⁴, Stephen E. Epstein⁷³, Daniel J. Rader^{75,4}

WTCCC: Nilesh J. Samani^{5,6}, John R. Thompson¹⁵, Peter S. Braund⁵, Christopher P. Nelson⁵, Benjamin J. Wright⁷⁶, Anthony J. Balmforth⁷⁷, Stephen G. Ball⁷⁸, Alistair S. Hall¹⁰, Wellcome Trust Case Control Consortium

Affiliations

1 Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; 2 Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA; 3 Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, MA, USA; 4 The Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA; 5 Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK; 6 Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, LE3 9QP, UK; 7 Institut für Integrative und Experimentelle Genomik, Universität zu Lübeck, Lübeck, Germany; 8 Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; 9 University of Texas Health Science Center, Human Genetics Center and Institute of Molecular Medicine, Houston, TX, USA; 10 Division of Cardiovascular and Neuronal Remodelling, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, UK; 11 Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, Regensburg, Germany; 12 Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Lübeck, Germany; 13 Science Center, Tampere University Hospital, Tampere, Finland; 14 The John & Jennifer Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Canada; 15 Department of Health Sciences, University of Leicester, Leicester, UK; 16 deCODE Genetics, 101 Reykjavik, Iceland; 17 University of Iceland, Faculty of Medicine, 101 Reykjavik, Iceland; 18 Hudson Alpha Institute, Huntsville, Alabama, USA; 19 Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada, K1Y 4W7; 20 Department of Biostatistics, Boston University School of Public Health, Boston, MA USA; 21 National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MA, USA; 22 The Blavatnik School of Computer Science and the Department of Molecular Microbiology and Biotechnology, Tel-Aviv University, Tel-Aviv, Israel, and the International Computer Science Institute, Berkeley, CA, USA; 23 Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA; 24 Department of Medicine, Harvard Medical School, Boston, MA, USA; 25 Research Methods, Univ Ottawa Heart Inst; 26 Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, Scania University Hospital, Lund University, Malmö, Sweden; 27 Division of Research, Kaiser Permanente, Oakland, CA, USA; 28 Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA; 29 Dept Cardiovascular Medicine, Cleveland Clinic; 30 Medizinische Klinik und Poliklinik, Johannes-Gutenberg Universität Mainz, Universitätsmedizin, Mainz, Germany; 31 Institut für Klinische Chemie und Laboratoriumsmedizin, Johannes-Gutenberg Universität Mainz, Universitätsmedizin, Mainz, Germany; 32 INSERM UMRS 937, Pierre and Marie Curie University (UPMC, Paris 6) and Medical School, Paris, France; 33 University of Texas Health Science Center, Human Genetics Center,

Houston, TX, USA; 34 Cardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, WA USA; 35 Cedars-Sinai Medical Center, Medical Genetics Institute, Los Angeles, CA, USA; 36 Erasmus Medical Center, Department of Epidemiology, Rotterdam, The Netherlands; 37 Boston University, School of Public Health, Boston, MA, USA; 38 University of Minnesota School of Public Health, Division of Epidemiology and Community Health, School of Public Health (A.R.F.), Minneapolis, MN, USA; 39 University of Washington, Cardiovascular Health Research Unit and Department of Medicine, Seattle, WA, USA; 40 Icelandic Heart Association, Kopavogur Iceland; 41 University of Iceland, Reykjavik, Iceland; 42 Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda MD, USA; 43 University of Washington, Department of Epidemiology, Seattle, WA, USA; 44 University of Washington, Department of Biostatistics, Seattle, WA, USA; 45 University of Washington, Department of Internal Medicine, Seattle, WA, USA; 46 University of Texas, School of Public Health, Houston, TX, USA; 47 National Heart, Lung and Blood Institute, Framingham Heart Study, Framingham, MA and Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; 48 Center for Health Studies, Group Health, Departments of Medicine, Epidemiology, and Health Services, Seattle, WA, USA; 49 The Wellcome Trust Sanger Institute, The Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; 50 Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle; 51 Boston University Medical Center, Boston, MA, USA; 52 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; 53 Department of Medicine, Landspítali University Hospital, 101 Reykjavik, Iceland; 54 Boston University School of Medicine, Framingham Heart Study, Framingham, MA, USA; 55 Institut für Klinische Molekularbiologie, Christian-Albrechts Universität, Kiel, Germany; 56 Institute of Epidemiology, Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg, Germany; 57 Institut für Humangenetik, Helmholtz Zentrum München, Deutsches Forschungszentrum für Umwelt und Gesundheit, Neuherberg, Germany; 58 Institute of Medical Information Science, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Germany; 59 Klinikum Grosshadern, Munich, Germany; 60 Institut für Humangenetik, Technische Universität München, Germany; 61 Division of Endocrinology and Diabetes, Graduate School of Molecular Endocrinology and Diabetes, University of Ulm, Ulm, Germany; 62 Division of Endocrinology, Department of Medicine, Medical University of Graz, Austria; 63 Synlab Center of Laboratory Diagnostics Heidelberg, Heidelberg, Germany; 64 Division of Clinical Chemistry, Department of Medicine, Albert Ludwigs University, Freiburg, Germany; 65 LURIC non profit LLC, Freiburg, Germany; 66 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Austria; 67 Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, University of Heidelberg, Germany; 68 Cardiology Group Frankfurt-Sachsenhausen, Frankfurt, Germany; 69 Cardiovascular Epidemiology and Genetics Group, Institut Municipal d'Investigació Mèdica, Barcelona; Ciber Epidemiología y Salud Pública

(CIBERSP), Spain; 70 Chronic Disease Epidemiology and Prevention Unit, Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland; 71 Department of Molecular Biology and Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, USA; 72 The Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 73 Cardiovascular Research Institute, Medstar Health Research Institute, Washington Hospital Center, Washington, DC 20010, USA; 74 Genetics Division and Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA; 75 The Institute for Translational Medicine and Therapeutics, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 76 Department of Cardiovascular Surgery, University of Leicester, Leicester, UK; 77 Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, LS2 9JT, UK; 78 LIGHT Research Institute, Faculty of Medicine and Health, University of Leeds, Leeds, UK; 79 DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck and München, Lübeck, Germany; 80: Deutsches Herzzentrum München, Technische Universität München München, Germany

Disclosures

Dr Absher reports receiving an NIH research grant for the ADVANCE study. Dr Assimes reports receiving an NIH research grant for the ADVANCE study. Dr Blankenberg reports receiving research grants from NGFNplus for Atherogenomics and from BMBF for CADomics. Dr Boerwinkle received research support from NIH/National Human Genome Research Institute (NHGRI), GWA for gene-environment interaction effects influencing CGD; NIH/NHLBI, Molecular epidemiology of essential hypertension; NIH/NHLBI, Genome-wide association for loci influencing coronary heart disease; NIH/NHLBI, Genetics of hypertension-associated treatment; NIH/NHLBI, Modeling DNA diversity in reverse cholesterol transport; NIH/NHLBI, 20-year changes in fitness and cardiovascular disease risk; NIH/NHLBI, Genetic epidemiology of sodium-lithium countertransport; NIH/National Institute of General Medical Sciences (NIGMS), Pharmacogenomic evaluation of antihypertensive responses; NIH/NIGMS, Genomic approaches to common chronic disease; NIH/NHLBI, Genes of the CYP450-derived eicosanoids in subclinical atherosclerosis; NIH/NHGRI-University of North Carolina, Chapel Hill, Genetic epidemiology of causal variants across the life course; and NIH/NHLBI, Building on GWAS for NHLBI-diseases: the CHARGE consortium. Dr Cupples reports receiving research grants from NIH/NHLBI, The Framingham Heart Study; NIH/NHLBI, Genome-wide association study of cardiac structure and function; NIH/NHLBI, Functional evaluation of GWAS loci for cardiovascular intermediate phenotypes; and NIH/NHLBI, Building on GWAS for NHLBI-diseases: the CHARGE consortium. Dr Halperin reports receiving research grants from NIH, subcontract Genome-wide

association study of Non Hodgkin's lymphoma; ISF, Efficient design and analysis of disease association studies; EU, consultant AtheroRemo; NSF, Methods for sequencing based associations; BSF, Searching for causal genetic variants in breast cancer and honoraria from Scripps Institute, UCLA. Dr Halperin also reports ownership interest in Navigenics. Dr Hengstenberg reports receiving research grants for EU Cardiogenics. Dr Holm reports receiving a research grant from NIH; providing expert witness consultation for the district court of Reykjavik; serving as member of the editorial board for decodeme, a service provided by deCODE Genetics; and employment with deCODE Genetics. Dr Li reports receiving research grant R01HG004517 and other research support in the form of coinvestigator on several NIH-funded grants and receiving honoraria from National Cancer Institute Division of Cancer Epidemiology and Genetics. Dr McPherson reports receiving research grants from Heart & Stroke Funds Ontario, CIHR, and CFI. Dr Rader reports receiving research grant support from GlaxoSmithKline. Dr Roberts reports receiving research grants from the Cystic Fibrosis Foundation, NIH, and Cancer Immunology and Hematology Branch; membership on the speakers bureau for AstraZeneca; receiving honoraria from Several; and serving as consultant/advisory board member for Celera. Dr Stewart reports receiving research grant support from CIHR, Genome-wide scan to identify coronary artery disease genes, and CIHR, Genetic basis of salt-sensitive hypertension in humans; other research support from CFI: Infrastructure support; and honoraria from the Institute for Biomedical Sciences, Academia Sinica, Taipei, Taiwan. Dr Thorleifsson is an employee of deCODE Genetics. Dr Thorsteinsdottir reports receiving research grants from NIH and EU; serving as an expert witness for a US trial; having stock options at deCODE Genetics; and having employment with deCODE Genetics. Dr Kathiresan reports receiving research grants from Pfizer, Discovery of type 2 diabetes genes, and Alnylam, Function of new lipid genes, and serving as consultant/advisory board member for DAIICHI SANKYO Merck. Dr Reilly reports receiving research grant support from GlaxoSmithKline. Dr Schunkert reports receiving research grants from the EU, project Cardiogenics; NGFN, project Atherogenomics; and CADnet BMBF. M. Preuss, L. Chen, and Drs König, Thompson, Erdmann, Hall, Laaksonen, März, Musunuru, Nelson, Burnett, Epstein, O'Donnell, Quertermous, Schillert, Stefansson, Voight, Wells, Ziegler, and Samani have no conflicts to disclose. Genotyping of PennCATH and MedStar was supported by Glaxo-SmithKline. Dawn M. Waterworth, Max C. Walker, and Vincent Mooser are employees of GlaxoSmithKline. PennCath/MedStar investigators acknowledge the support of Eliot Ohlstein, Dan Burns and Allen Roses at GlaxoSmithKline.